433 related articles for article (PubMed ID: 22633080)
21. [Treatment of tuberculosis].
Ben Amar J; Dhahri B; Aouina H; Azzabi S; Baccar MA; El Gharbi L; Bouacha H
Rev Pneumol Clin; 2015; 71(2-3):122-9. PubMed ID: 25434510
[TBL] [Abstract][Full Text] [Related]
22. Treatment of latent tuberculosis infection: a network meta-analysis.
Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
[TBL] [Abstract][Full Text] [Related]
23. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
Ziakas PD; Mylonakis E
Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936
[TBL] [Abstract][Full Text] [Related]
24. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
25. [Cutaneous reaction after pyrazinamide initiation].
Mulliez P; Mbassi Fouda FL; Roy Saint-Georges F
Med Mal Infect; 2011 Sep; 41(9):499-500. PubMed ID: 21458177
[No Abstract] [Full Text] [Related]
26. [Procedure in case of suspected mycobacterial infection of lymph nodes of the neck. 2. Therapy].
Göpel B; Götte K
Laryngorhinootologie; 2005 Aug; 84(8):610-9; quiz 621-2. PubMed ID: 16080064
[TBL] [Abstract][Full Text] [Related]
27. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
28. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
Lardizabal A; Passannante M; Kojakali F; Hayden C; Reichman LB
Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986
[TBL] [Abstract][Full Text] [Related]
30. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
[TBL] [Abstract][Full Text] [Related]
31. Clinical practice. Latent tuberculosis infection.
Jasmer RM; Nahid P; Hopewell PC
N Engl J Med; 2002 Dec; 347(23):1860-6. PubMed ID: 12466511
[No Abstract] [Full Text] [Related]
32. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
[TBL] [Abstract][Full Text] [Related]
33. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong.
Leung CC; Law WS; Chang KC; Tam CM; Yew WW; Chan CK; Wong MY
Chest; 2003 Dec; 124(6):2112-8. PubMed ID: 14665488
[TBL] [Abstract][Full Text] [Related]
34. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN
Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755
[TBL] [Abstract][Full Text] [Related]
35. Gynaecomastia during antituberculosis chemotherapy with isoniazid.
Dixit R; Sharma S; Nawal CL
J Assoc Physicians India; 2008 May; 56():390-1. PubMed ID: 18700651
[No Abstract] [Full Text] [Related]
36. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
Cook PP
Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
[No Abstract] [Full Text] [Related]
37. Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens.
Lincoln T; Brannan GL; Lynch V; Conklin TJ; Clancey T; Rose DN; Tuthill RJ
Int J Tuberc Lung Dis; 2004 Mar; 8(3):306-11. PubMed ID: 15139468
[TBL] [Abstract][Full Text] [Related]
38. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.
Li J; Munsiff SS; Tarantino T; Dorsinville M
Int J Infect Dis; 2010 Apr; 14(4):e292-7. PubMed ID: 19656705
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
[TBL] [Abstract][Full Text] [Related]
40. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
